Methotrexate 2.50mg 50 Tab – Professional Description:

Methotrexate is an antimetabolite and antifolate agent indicated for the treatment of certain neoplastic diseases, various malignancies (including acute lymphoblastic leukemia, breast cancer, non-Hodgkin’s lymphoma), severe psoriasis, and rheumatoid arthritis. It inhibits dihydrofolate reductase, disrupting DNA synthesis and cell replication, particularly targeting rapidly dividing cells.

---

Forms, Dosages & Presentations from India: {Tablets}

• • 2.5 mg – Blister packs of 10, 20, 30 tablets
  • 5 mg – Blister packs of 10, 20 tablets
  • 7.5 mg – Blister packs of 10 tablets
  • 10 mg – Blister packs of 10 tablets
  • 15 mg – Blister packs of 10 tablets

Injectable Solutions:

• • 25 mg/mL – 2 mL vials, 5 mL vials, 10 mL vials
  • 50 mg/2 mL ampoules
  • 500 mg/5 mL vials
  • 1,000 mg/10 mL vials

Prefilled Syringes (subcutaneous use):

• • 7.5 mg/0.3 mL
  • 10 mg/0.4 mL
  • 15 mg/0.6 mL
  • 20 mg/0.8 mL
  • 25 mg/1.0 mL

(Manufacturers: Zydus Cadila, Intas, Cipla, Alkem, Sun Pharma, Hetero Labs, among others.)

---

 

USA Products – NDC Numbers (Select Listings):

• • Methotrexate 2.5 mg Tablets: NDC 0093-0706-01 (Teva Pharmaceuticals)
  • Methotrexate Injection 25 mg/mL, 2 mL vial: NDC 55150-218-02 (Hikma Pharmaceuticals)
  • Methotrexate Injection 50 mg/2 mL vial: NDC 61703-004-21 (Fresenius Kabi USA)

Mexican Health System (IMSS/Instituto de Salud) - CLAVE Numbers:

• • Methotrexato 2.5 mg 50 Tabletas → Clave 010.000.1759.00
  • Methotrexato 50 mg 1 Vial Inyectable → Clave 010.000.1760.00
  • Methotrexato 50 mg 10 Vial Pack Inyectable → Clave 010.000.1760.01
  • Methotrexato 500 mg 1 Vial Inyectable → Clave 010.000.1776.00
  • Methotrexato 1 gm 1 Vial Inyecatable → Clave:010.000.2194.00

(Note: These are confirmed entries within the "Compendio Nacional de Insumos para la Salud México")  

---

 

Dosage Forms:

• • Oral Tablets
  • Injectable Solutions (Intravenous, Subcutaneous, Intramuscular)
  • Prefilled Syringes (Subcutaneous)

Size:

• • Tablets: Typically 10 to 30 tablets per box or blister
  • Injectables: 2 mL, 5 mL, 10 mL, or larger vials

Reference Brands:

• • Trexall® (tablets - USA)
  • Rheumatrex® (discontinued but historically reference)
  • Otrexup® (prefilled syringe)
  • Rasuvo® (prefilled syringe)
  • Metoject® (prefilled syringe, marketed internationally)

Case Quantity (Typical Export Packaging):

• • Tablets: 1,000 to 3,000 tablets per master carton (100 blisters of 10-30 each)
  • Injectables: 100 to 250 vials per master carton, depending on volume (2mL to 10mL)
  • Prefilled Syringes: 50 to 100 units per carton

Product Shelf Life:

• • Tablets: 24 to 36 months from manufacturing date
  • Injectables: 24 to 36 months (strict storage at 2°C–8°C recommended for solutions)
  • Prefilled Syringes: 24 months

Drug Category:

1. 1. Antineoplastic Agent
   2. Immunosuppressant
   3. Antirheumatic Agent (Disease-Modifying - DMARD)
   4. Antimetabolite